Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), through unit Shanghai Henlius Biotech, received approval from the US Food and Drug Administration for the biologics license applications of denosumab injection, a drug used to prevent osteoporosis and skeletal defects,

The approval is for the drug's two specifications, the Bildyos, with a 60 milligram/milliliter measurement, and Bilprevda, with a 120 mg/1.7 mL measurement.

The Chinese pharmaceutical company's Shanghai shares rose over 1% during morning trade.